Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HeadStart4: Intensive Chemotherapy for Newly Diagnosed Children With Medulloblastoma and CNS Embryonal Tumors
NCT02875314Phase 4Active, not recruiting
- Start
- Sep 2015
- Primary completion
- Dec 2030
- Modality
- DNA Intercalators/Alkylators
- Countries
- 3
01
Overview
Phase 4, randomised, open-label trial of thiotepa, carboplatin and etoposide in medulloblastoma and central nervous system embryonal tumor (3 arms). Primary endpoints: Event-Free Survival at 5 years and Overall Survival at 5 years. Started Sep 2015; status: active, not recruiting.
02
Drugs
thiotepacarboplatinetoposide
03
Conditions
medulloblastomacentral nervous system embryonal tumor
Beyond the preview
Go deeper on NCT02875314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02875314.